Orphan drugs and the NHS: should we value rarity?
- PMID: 16254305
- PMCID: PMC1273462
- DOI: 10.1136/bmj.331.7523.1016
Orphan drugs and the NHS: should we value rarity?
Abstract
The growing number and costs of drugs for rare diseases are straining healthcare budgets. Decisions on funding these treatments need to be made on a sound basis
Figures
Comment in
-
Orphan drugs and the NHS: fairness in health care entails more than cost effectiveness.BMJ. 2005 Nov 12;331(7525):1144-5. doi: 10.1136/bmj.331.7525.1144-c. BMJ. 2005. PMID: 16282416 Free PMC article. No abstract available.
-
Orphan drugs and the NHS: consider whom drug regulation is designed to protect.BMJ. 2005 Nov 12;331(7525):1144. doi: 10.1136/bmj.331.7525.1144-b. BMJ. 2005. PMID: 16282417 Free PMC article. No abstract available.
Similar articles
-
Orphan drugs and the NHS: consider whom drug regulation is designed to protect.BMJ. 2005 Nov 12;331(7525):1144. doi: 10.1136/bmj.331.7525.1144-b. BMJ. 2005. PMID: 16282417 Free PMC article. No abstract available.
-
Orphan drugs and the NHS: fairness in health care entails more than cost effectiveness.BMJ. 2005 Nov 12;331(7525):1144-5. doi: 10.1136/bmj.331.7525.1144-c. BMJ. 2005. PMID: 16282416 Free PMC article. No abstract available.
-
[Orphan drugs: drugs for rare diseases].Dtsch Med Wochenschr. 2010 May;135(18):p17. Dtsch Med Wochenschr. 2010. PMID: 20455291 German. No abstract available.
-
The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space.Drug Dev Res. 2014 Jun;75(4):231-4. doi: 10.1002/ddr.21176. Epub 2014 May 14. Drug Dev Res. 2014. PMID: 24829189 Review.
-
Drugs for exceptionally rare diseases: do they deserve special status for funding?QJM. 2005 Nov;98(11):829-36. doi: 10.1093/qjmed/hci128. Epub 2005 Oct 3. QJM. 2005. PMID: 16203824 Review.
Cited by
-
Establishing a reasonable price for an orphan drug.Cost Eff Resour Alloc. 2020 Sep 4;18:31. doi: 10.1186/s12962-020-00223-x. eCollection 2020. Cost Eff Resour Alloc. 2020. PMID: 32908456 Free PMC article.
-
Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67.BMJ. 2010 Sep 22;341:c4715. doi: 10.1136/bmj.c4715. BMJ. 2010. PMID: 20861122 Free PMC article.
-
Commissioning for rare diseases: view from the frontline.BMJ. 2005 Oct 29;331(7523):1019-21. doi: 10.1136/bmj.331.7523.1019. BMJ. 2005. PMID: 16254306 Free PMC article. Review.
-
Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems.Eur J Health Econ. 2015 Mar;16(2):113-8. doi: 10.1007/s10198-014-0639-8. Eur J Health Econ. 2015. PMID: 25355295 No abstract available.
-
A systematic review of moral reasons on orphan drug reimbursement.Orphanet J Rare Dis. 2021 Jun 30;16(1):292. doi: 10.1186/s13023-021-01925-y. Orphanet J Rare Dis. 2021. PMID: 34193232 Free PMC article.
References
-
- National Institute for Clinical Excellence. NHS should consider paying premium prices for drugs to treat patients with very rare diseases says NICE Citizen's Council. Press release 26 Jan. www.nice.org.uk/pdf/2005_002_CitizensCouncilreport.pdf (accessed 21 Feb 2005).
-
- Department of Health. National designation and funding of treatment for patients with lysosomal storage disorders. www.dh.gov.uk/assetRoot/04/09/22/10/04092210.pdf (accessed 22 Feb 2005).
-
- Rawlins M. Managing rare diseases. London: Royal College of Physicians, 2004.
-
- National Institute for Clinical Excellence. Final appraisal determination: imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours. London: NICE, 2004 www.nice.org.uk/page.aspx?o=216331 (accessed 18 Aug 2005).
-
- National Institute for Clinical Excellence. Guide to the methods of health technology appraisal. London: NICE, 2003.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical